Resources Here you can find resources to download and access related to Ultomiris® as an add-on to standard therapy for the treatment of adult patients with gMG who are (AChR) antibody-positive.
Please click the links below to be redirected to a third-party website, where you can access and find more information on these selected publications.
Alexion is not the copyright holder of either the journal or the articles – such copyright(s) is/are held by the publisher(s) and/or the author(s) of the journal and/or article as appropriate. Alexion has provided the weblinks to the full article(s) merely to assist the reader and on the basis that the relevant article(s) is/are either available as ‘open access’ or via a subscription service which the reader may already subscribe to. Alexion assumes no responsibility for ascertaining if the reader has appropriate copyright licence for use of the relevant article and Alexion makes no attempt to provide any licence or permission to the reader – all such permissions and ownership rest exclusively with their owners.

Adverse Event Reporting

Please report any adverse reactions via your national reporting system. Adverse events should also be reported to Alexion pharmaceuticals by the following link: https://contactazmedical.astrazeneca.com

ULTOMIRIS® (ravulizumab) EU Summary of Product Characteristics. Available from: https://www.ema.europa.eu/en/documents/product-information/ultomiris-epar-product-information_en.pdf. Last accessed: September 2024.
advance I am a healthcare professional registered in the EU I am not a
healthcare professional